systemic triple therapy in metastatic hormone-sensitive prostate cancer
Published 2 years ago • 1.3K plays • Length 0:47Download video MP4
Download video MP3
Similar videos
-
4:05
evaluating triplet therapy in metastatic hormone sensitive prostate cancer
-
2:27
triplet therapy for metastatic hormone-sensitive prostate cancer
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
13:09
pca commentary: metastatic hormone sensitive prostate cancer (mhspc): many treatment options
-
3:20
radiation therapy for the local treatment of metastatic hormone-sensitive prostate cancer
-
5:06
psmaddition: 177lu-psma-617 plus soc vs. soc alone in metastatic hormone-sensitive prostate cancer
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
2:25
subgroups of metastatic hormone-sensitive prostate cancer (mhspc)
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
5:31
updates on the systemic treatment of metastatic hspc
-
5:16
exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
-
6:53
perspectives on metastatic hormone-sensitive prostate cancer | bayer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
16:26
patient selection in metastatic hormone-sensitive prostate cancer (mhspc)
-
46:40
updates on management of metastatic hormone-sensitive prostate cancer
-
48:10
urowebinar: paradigm shifts in metastatic hormone sensitive prostate cancer: recnt treatmnt dvlpmnts
-
0:44
how can systemic triple therapy benefit metastatic hormone-sensitive prostate cancer?